INS and kidney disorder: Only a very low proportion of incident treatments of SGLT2i and GLP1-RA had a history of heart failure or nephropathy, compared to incident treatments of glinides and insulin (heart failure: 5.1% and 5.9% vs. 10.2% and 11.6%, respectively (p-values < 0.001 for both comparisons); nephropathy: 7.7% and 7.4% vs. 11.2% and 12.4%, respectively (p-values < 0.001 for both comparisons)).